The TGF-β pathway are increased in most forms of CKD in humans and experimental animals and controls including fibrogenesis, apoptosis, epithelial-to-mesenchymal transition, and inflammation leading to glomerulosclerosis and tubulointerstitial fibrosis [73]. Here, TGFB1 is linked to chronic kidney disease.